Refine by
Ischemic Heart Equipment & Supplies
12 equipment items found
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart ...
Manufactured by:JD Bioscience Inc. (JDB) based inBuk-gu, SOUTH KOREA
JDB is developing a novel drug candidate for heart disease that can rescue heart function at a cellular level, and can eventually help improving heart ...
Manufactured by:P+F Products + Features GMBH based inVienna, AUSTRIA
The EFIL+ Sirolimus Eluting Stent System is a combination product comprised of two regulated components: a device (a coronary stent system) and a drug product (a formulation of Sirolimus contained in a polymer coating) pre mounted on balloon catheter between two platinum iridium radio opaque marker bands. EFIL+ uses a validated formulation of low dose Sirolimus (1.30µg/mm ) timed to elute ...
Manufactured by:Medispec based inGaithersburg, MARYLAND (USA)
Medispec’s ED1000 is a medical device that uses advanced acoustics technology based on electrohydraulic power. This technology has proven to be effective in cardiology, with recent success in reversible ischemic tissues of the heart. EDSWT utilizes low-intensity extracorporeal shock waves, focusing on blood vessels and encouraging neovascularization in the ...
Manufactured by:Medispec based inGaithersburg, MARYLAND (USA)
The ESMR therapy is a non-invasive therapy approach using Extracorporeal Shockwave technology for Myocardial Revascularization. Ischemic myocardial areas no longer accessible by conventional revascularization therapies could be treated with the Cardiospec ESMR therapy to relieve symptoms resulted from the myocardial ischemia. The treatment is performed using a shock wave generator that is ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late INa ) with IC50 values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, ...
Manufactured by:Circle Cardiovascular Imaging Inc. based inCalgary, ALBERTA (CANADA)
cvi42 for Cardiac MRI has the most clinically cleared tools for diagnosis, and the most accurate tools to quantify and qualify for research purposes. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Hydrochlorothiazid-d2 is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Hydrochlorothiazide-13C6 is the 13C labeled Hydrochlorothiazide[1]. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive ...
Manufactured by:Biocardia, Inc. based inSunnyvale, CALIFORNIA (USA)
The investigational CardiAMP™ Cell Therapy is designed to be a comprehensive biotherapeutic heart failure solution, incorporating: a proprietary molecular diagnostic to characterize the potency of a patient’s own bone marrow cells and determine if they are an optimal candidate for therapy. a point of care processing platform to prepare cells at the patient’s bedside. an ...